First of all, I think Lilly's Zepbound strategy is brilliant. It should open up a larger market for the company's obesity drug. As James Zervos, chief operating officer with Obesity Action ...

and Henry Meds—accusing them of deceptively marketing and selling compounded versions of its FDA-approved drugs, Mounjaro and Zepbound. Lilly alleges these companies are promoting untested and ...

Eli Lilly and ... (May 1st before market open) comes during a period of remarkable expansion in the company's GLP-1 business. Investors will focus on Mounjaro and Zepbound revenue, production ...

NEW YORK — CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo Nordisk will become the preferred options on its standard formulary, or list of covered drugs, as of July 1.

But the Agars, who live in Minnesota, aren't taking Eli Lilly's Zepbound ... They call it the "gray market." Zepbound and the compounded alternatives have to be sterile for injection, so a ...

Eli Lilly has seen US prescriptions for its Zepbound ... but its market value has halved to about $310 billion. Camilla Sylvest, Novo’s head of commercial strategy and corporate affairs and ...